

# Interim Report January-March 2021 for Amniotics AB (publ)

### Financial summary first quarter 2021

- Total revenues: 0 (0) KSEK.
- Operating profit (EBITA): -12 073 (-5 488)
   KSEK.
- Result for the period: -12 500 (5 887) KSEK
- Earnings per share: -483,17 (-318,48) SEK.
- Cash and cash equivalents at the end of the reporting period: 22 533 (195) KSEK.
- Equity/assets ratio as per the end of the reporting period: 80,55 (53,81) %.

### Operations during the first quarter of 2021

Amniotics™ has worked diligently to ensure further development of IP and production of GMP grade cells

# Significant events after the end of the reporting period

The Annual General Meeting (AGM) was held on April 15, where four new board members were elected, and the board was given permission to issue new shares.

# Amniotics AB (publ)

Amniotics vision is to contribute to the successful treatment of human diseases by providing the very best stem cells for medical applications. We are devoted to developing innovative life-changing and regenerative treatments for patients.

Amniotics business concept is to deliver safe and effective innovative therapies to patients with unmet medical needs.

The strategy is to develop treatments for diseases with severe inflammatory and fibrotic components, where tissue-relevant stem cells can be expected to have an impact and be life-changing treatments.

The objective is to successfully conduct and complete planned clinical trials with our tissue-relevant Mesenchymal Stem Cells (MSCs).

Amniotic is presently producing technical batches of our lung specific MSCs (PulmoStem™) and following the GMP certification of our premises and approval of our Tissue Establishment, Amniotics™ is progressing with speed. With the results from Amniotics™ preclinical studies and the characterization of the quality attributes of the cells (sterility, identity, purity, injectability), Amniotics is moving towards clinical trials, with a focus set for treatment of ARDS/COVID-19.

The company is public and aiming for a listing on the Swedish marketplace Nasdaq First North Growth Market

The company's Certified Advisor is RedEye AB, +46 812 157 690 certifiedadviser@redeye.se

# A word from the CEO

First quarter 2021 has been a very busy period During the first quarter of 2021, Amniotics AB has prepared for the clinical trial as well as for going public on Nasdag First North Growth.

The core documents for the clinical trial in COVID-19 patients have been finalized. These documents; the Investigator Brochure (IB), Clinical Study Protocol (CSP) and Investigational Medicinal Product Dossier (IMPD) have along with other documents has been submitted for the clinical trial application. Amniotics has further during the first quarter continued progressing its IP portfolio by submitting additional patents. Furthemore Amniotics has started to scale the organization and board for life as a listed company, as the company is preparing for a listing on the Swedish marketplace Nasdaq First North Growth.

# New board and Authorization to carry emissions

On April 15, the Annual General Meeting was held. The major shareholder Christer Fåhraeus handed over the chairmanship to Danish Peter Buhl Jensen, who has, among other things, brought Oncology Venture to the stock exchange as well as developing the Danish Research Park Symbion. Other new board members are Ingrid Atteryd Heiman, Christopher Bravery and Fredrik Tiberg. This reinforcement of the board adds needed competence in listing, clinical development, and regulatory affairs.

The AGM did also authorize the board to decide and carry out emissions of shares up to the maximum level allowed according to the Articles of Association. This permission to emit by the board of directors is

valid until the next coming AGM in 2022. The permission may only be used to ensure recapitalization and ownership dispersal while preparing for/during a listing of Amniotics on the marketplace. The up-coming periods with both listing and clinical development call for reinforcement of the board.

### 2020 met important milestones

During the past year Amniotics has received more than 62 MSEK in new investments, while also managed to get certified as a Tissue Establishment as well as certified as a GMP (Good Manufacturing Practice) plant from the Swedish Medical Products Agency (Läkemedelsverket). The year 2020 also resulted in performing pre-clinical studies for respiratory indications. Following Manufacturing Authorization by the Swedish Medical Products Agency (Läkemedelsverket), Amniotics GMP plant will allow the company to produce PulmoStem™ inhouse aimed at clinical studies, while the capacity of the plant opens for additional collaborations with other pharmaceutical companies or investigators.

### Looking forward

With new talented people on board both among management with e.g. a new CFO and partly a new board with an experienced Chairman, I feel that we are prepared to meet expected milestones.

# Income Statement in summary

	First Quarter		YTD December	
KSEK	2021	2020	2020	2019
Net sales	0	0	0	0
Other operating income	3	3	38	13
Total operating income	3	3	38	13
Other operating expenses	-8 670	-3 709	-21 586	-4 870
Employee benefits expenses	-3 337	-1 776	-7 842	-5 273
Other operating costs	-70	-6	-17	-16
Operating result before depreciation and amortisation (EBITDA)	-12 073	-5 488	-29 408	-10 146
Depreciation and amortisation	-426	-400	-1 586	-281
Operating result (EBIT)	-12 500	-5 887	-30 994	-10 428
Finance net	0	-1	-3	-1
Result before tax	-12 500	-5 888	-30 997	-10 428
Income tax	0	0	0	0
Result for the period	-12 500	-5 888	-30 997	-10 428

# Balance sheet in summary

	First Quarter		YTD December	
KSEK	2021	2020	2020	2019
Assets				
Subscribed but not paid share capital			37 846	
Fixed assets				
Intangible assets	4 023	3 327	3 752	3 327
Equipment and installations	8 947	8 121	9 374	5 919
Total fixed assets	12 970	11 448	13 125	9 246
Total lived dissets	12 010	11 440	10 120	0 240
Current assets				
Other receivables	1 353	1 403	1 970	1 345
Cash and bank balances	22 533	195	510	6 027
Total current assets	23 886	1 598	2 480	7 373
Total assets	36 856	13 046	53 451	16 619
Shareholders' Equity and Liabilities				
Restricted equity				
Share capital	700	185	604	185
Not registered share capital			96	
Reserve for development expenses	167	29	167	29
Non- restricted equity				
Share premium reserve	90 549	20 132	90 549	20 132
Accumulated loss including profit/loss for the period	-61 729	-13 325	-49 229	-7 437
Total shareholders' equity	29 687	7 021	42 186	12 909
Liabilities				
Liabilities to credit institutions, long-term	599	0	599	0
Current liabilities	6 571	6 026	10 666	3 710
Total liabilities	7 169	6 026	11 265	3 710
Total charaboldara' aguity and liabilities	26 956	12.046	E2 4E4	16 640
Total shareholders' equity and liabilities	36 856	13 046	53 451	16 619

# Summary report of Changes in the shareholders' equity

	First Quarter		YTD December	
KSEK	2021	2020	2020	2019
Opening balance	42 186	12 909	12 909	3 124
Issue of shares			60 275	20 213
Loss for the period	-12 500	-5 888	-30 997	-10 428
Equity at end of period	29 687	7 021	42 186	12 909
Earnings / (loss) per share, SEK	-483,17	-318,48	-1 198,19	-564,07
Earnings per share, fully diluted, SEK	-483,17	-318,48	-1 198,19	-564,07
Average number of shares during the period	25 870	18 488	25 870	18 488
Average shares outstanding during the period	25 870	18 488	25 870	18 488
Total outstanding shares	25 870	18 488	25 870	18 488

# Cash Flow statement in summary

	Fourth Quarter		YTD December	
KSEK	2021	2020	2020	2019
Cash flow from operations during the period	-12 926	-6 288	-32 584	-10 710
Changes in working capital	34 368	2 258	-31 515	1 844
Cash flow from operations after change in working capital	21 442	-4 030	-64 098	-8 866
Cash flow from investing activities	582	-1 802	-2 293	-6 397
Cash flow from financing activities	0	0	60 874	20 213
Cash flow for the period	22 024	-5 832	-5 518	4 950
Cash and cash equivalents at the beginning of the period	510	6 027	6 027	1 077
Cash and cash equivalents at the end of the period	22 533	195	510	6 027

# Financial key ratios

	First Quarter		YTD December	
KSEK	2021	2020	2020	2019
Earnings per share before dilution SEK	-483,17	-318,48	-1 198,19	-564,07
Earnings per share after dilution SEK	-483,17	-318,48	-1 198,19	-564,07
Shareholders' equity per share, SEK	1 147,54	379,73	1 630,71	698,21
Equity/assets ratio, %	81	52	79	78

# Share capital development

Year	Event	Total share-	Change	Total	Change	Quotient
		Capital (SEK)	(SEK)	shares	shares	(SEK)
2015	Company registration	50 000	50 000	5 000	5 000	10,00
2017	New share issue	64 300	14 300	6 430	1 430	10,00
2017	New share issue	75 770	11 470	7 577	1 147	10,00
2018	New share issue	90 050	14 280	9 005	1 428	10,00
2018	New share issue	104 340	14 290	10 434	1 429	10,00
2019	New share issue	127 190	22 850	12 719	2 285	10,00
2019	New share issue	171 190	44 000	17 119	4 400	10,00
2019	New share issue	184 880	13 690	18 488	1 369	10,00
2020	Bonus issue	500 000	315 120	18 488	0	27,04
2020	New share issue	603 986	103 986	22 333	3 845	27,04
2020	New share issue	699 643	95 657	25 870	3 537	27,04
At end of	the period	699 643		25 870		27,04

# Financial information

# Income and profit/loss

Net sales for the quarter-amounts to KSEK 0 (0). Other operating income amounts to TSEK 3 (3). Operating loss for the period amounts to TSEK -12 500 (-5 887). The principal costs during the period are mainly attributable to research and development, and fees to consultants and personnel expenses.

# Cash flow and financial position

Cash flow for the period January - March amounts to TSEK 21 442. Cash and bank balances at the close of the period amount to TSEK 22 533. The equity/assets ratio amounts to 80,55%.

# Liquidity and financing

The board and company management are assessing alternatives to secure the company's long-term capital requirement on an ongoing basis. The Board believes that the existing working capital is sufficient to run the Company over the next twelve months

### The share

The number of shares at the end of the period amount to 25 870, with a quotient value of SEK 27,04. The average number of shares for the period amounts to 25 870. All shares are of the same class and have the same voting right.

### Personnel

The average number of employees in the group amounted during the period to 12 (8) persons.

# Other Information

### Risks and uncertainty factors

A pharmaceutical development company such as Amniotics is exposed to significant operational and financial risk. Many factors can have a negative impact on the probability of commercial success. The risks to which the Company is exposed in its current phase and the risk that the necessary financing cannot be secured. During the quarter no

significant changes with respect to these risks or uncertainty factors have arisen.

# Principles for preparation of the interim report

Amniotics prepares its financial reports in accordance with the Swedish Annual Accounts Act and BFNAR 2012:1 (K3) Annual Accounts and Consolidated Accounts. The same accounting principles have been applied in this interim report as were applied in the most recent annual report. Assets, provisions and liabilities have been valued at cost unless otherwise specified. Transactions denominated in foreign currency are converted at the spot rate in effect on the transaction date.

#### Effects of the covid-19 pandemic

The covid-19 pandemic is impacting, and will continue to impact, all aspects of society for a very long time to come. No one can predict the exact magnitude of the outcomes and effects of this unique
Situation. The immediate effects on Amniotics' operations are so far limited. We continue our work as usual but are making use of digital technology to minimize the number of social contacts. At present, we foresee limited material delays in either of our projects. Amniotics' monitors continuously the development of the covid-19 pandemic and its consequences for the company.

### Review by auditors

This report has not been reviewed by the company's auditors.

#### Financial calendar 2021

Interim Report, Q2 2021 August 27 2021 Interim Report, Q3 2021 November 12 2021

# For further information, please contact:

Amniotics AB (publ) Medicon Village, SE-223 81 Lund, Sweden

Kåre Engkilde, CEO

Tel: Tel: +46 (0)72 327 85 20 E-mail: ke@amniotics.com

### Certification by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Company's business activities, financial position and results of operations and describes significant risks and uncertainties facing the Company.

# Lund, May 6, 2021 Amniotics AB (publ)

Peter Buhl Jensen Chairman

Lars Stigsson
Board member

Ingrid Atteryd Heiman Board member Christer Fåhraeus Board member

Marcus Larsson Board member

Christopher Bravery Board member

Anders Månsson Board member

Fredrik Tiberg Board member This information is information that Amniotics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 6th, 2021.

# Glossary

**GMP:** Good manufacturing practice is a system or structure for ensuring that products are consistently produced and controlled according to quality standards. Thereby, minimizing the risks involved in pharmaceutical production.

**IMPD:** The Investigational Medicinal Product Dossier (IMPD) is one of several pieces of Investigational Medicinal Product (IMP) related data required whenever the performance of a clinical trial is intended.

**IB:** The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the

study of the product(s) in human subjects. Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol.

MSC: Mesenchymal stem cells are multipotent stem cells that are present in multiple tissues. They can self-renew by dividing and can differentiate into multiple tissues including bone, cartilage, muscle and fat cells, and connective tissue.